BridgeMD
New treatment option for Vomiting in Infants and/or Children
Official title RCT of Olanzapine for Control of CIV in Children Receiving Highly Emetogenic Chemotherapy
ClinicalTrials.gov ID: NCT03118986
What this study is testing
What is Olanzapine?
Olanzapine is an investigational medicine, given as an once-daily pill taken by mouth, being studied as a potential treatment for vomiting in infants and/or children.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Chemotherapy-induced nausea and vomiting (CINV) are among the most bothersome symptoms during cancer treatment according to children and their parents. Most children receiving highly emetogenic chemotherapy (HEC), including those receiving hematopoietic stem cell transplant (HSCT) conditioning, experience CIV despite receiving antiemetic prophylaxis.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 30 to 18
You may be able to join if
- Planned receipt of HEC or cyclophosphamide ≥ 1 g/m2/day (≥ 33 mg/kg/day) for cancer treatment or autologous or allogeneic HSCT conditioning.81,82...
- Plasma creatinine within 1.5 times the upper limit of normal for age.
- Amylase within age-appropriate limits
- Plasma conjugated bilirubin within ≤ 3x upper limit of normal for age unless attributable to Gilbert's Syndrome
- ALT ≤ 5x upper limit of normal for age Baseline ECG within the month prior to study drug administration without known clinically significant...
The study team makes the final eligibility decision.
Where it's taking place
- San Francisco, California, United States
- Kansas City, Missouri, United States
- New York, New York, United States
- Chapel Hill, North Carolina, United States
- Columbus, Ohio, United States
- Charleston, South Carolina, United States
- Winnipeg, Manitoba, Canada
- Toronto, Ontario, Canada
- Montreal, Quebec, Canada
- New Delhi, National Capital Territory of Delhi, India
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 30 months to 18 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Francisco, California, United States; Kansas City, Missouri, United States; New York, New York, United States; Chapel Hill, North Carolina, United States; Columbus, Ohio, United States; Charleston, South Carolina, United States and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.